');
} else {
var query = elem.find('.keywords').html();
$.ajax({
context: elem,
url: 'https://wn.com/api/upge/cheetah-search-adv/video',
cache: true,
data: {
'query': query
},
dataType: 'jsonp',
success: function(text) {
if (text.length > 0) {
video_id = text[0].id;
elem.find('.player').html('
');
}
}
});
}
}
var stopAllYouTubeVideos = function() {
var iframes = document.querySelectorAll('iframe');
Array.prototype.forEach.call(iframes, function(iframe) {
iframe.contentWindow.postMessage(JSON.stringify({ event: 'command', func: 'pauseVideo' }), '*');
});
}
jQuery(function() {
jQuery(".playVideo").live("click", function() {
if(!$(this).hasClass("played")){
stopAllYouTubeVideos();
var elem = $(this);
setTimeout(function(){
mouseOverMe(elem);
}, 1000);
}
});
jQuery(".description_box .expandContent").live("click", function() {
elem = $(this).parent().parent().parent().find('.descContent');
if(elem.height() > 51) {
elem.css('height', '44px');
$(this).html('Show More
');
}else{
elem.css('height', 'auto');
$(this).html('Hide
');
}
});
jQuery('.interview-play-off').click(function() {
$(".interview-play-off").hide();
$(".interview-play").show();
$(".videoplayer-control-pause").click();
});
jQuery(".video-desc .show_author_videos").live("click", function() {
query = $(this).attr('title');
container = $(this).parent().parent().parent().find('.video-author-thumbs');
$(this).parent().parent().parent().find('.video-author-thumbs').css('height', '220px');
jQuery.ajax({
url: '/api/upge/cheetah-photo-search/videoresults',
data: {'query': query},
success: function(text) {
if(!text) { text = i18n("No results"); }
container.html(jQuery(text));
}
});
});
});
// -->
Latest News for: aad
Edit
PR Newswire
27 Mar 2026
"The findings being presented at AAD reinforce that staging alone does not tell the whole story," said Harrison Nguyen M.D., MBA, MPH, lead study author and double board-certified dermatologist and fellowship-trained Mohs micrographic surgeon.
Edit
PR Newswire
27 Mar 2026
"The data at AAD showed that nearly ninety percent of patients treated with bimekizumab had no acute exacerbations of symptoms at scheduled visits for up to three years, indicating its potential ability to provide durable, long-term control." ... AAD.
Edit
PR Newswire
25 Mar 2026
"We are incredibly excited to be at AAD this year and to share the progress Revance has made across our entire aesthetics, regenerative and skincare portfolio," said Nadeem Moiz, CEO of Revance.